LINDSEY TETEN: Open Payments
NPI 1164838967 · NEBRASKA CITY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,145 in 81 payments from 16 companies in 2025. Trend: 2023 $837 · 2024 $1,299 · 2025 $1,145
Food & beverage: $1,144Education: $1
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $340 |
| Otsuka America Pharmaceutical, Inc. | 16 | $202 |
| Vanda Pharmaceuticals Inc. | 13 | $145 |
| HARMONY BIOSCIENCES LLC | 5 | $85 |
| Neurocrine BioSciences, Inc. | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Neos Therapeutics, LP | 3 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
Products named: VRAYLAR, REXULTI, HETLIOZ, WAKIX, FANAPT, ABILIFY MAINTENA, ABILIFY ASIMTUFII, INGREZZA.
Industry payments across NE — which companies pay providers there.
